PTC THERAPEUTICS, INC. - 8-K Filing

PTC Therapeutics completed acquisition of ST-920 gene therapy for Fabry disease and expects BLA submission in Q4 2026. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Information, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PTCT

Read the full article at SEC EDGAR

More Regulatory news